If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The Memphis Flyer is Memphis’ alternative newsweekly, serving the metro Memphis area of nearly a million residents. The Flyer was started in 1989 by Contemporary Media, Inc., the locally owned ...

GLP-1 medications like Semaglutide, Tirzepatide, and even oral options that target key metabolic processes. TMatesis positioning itself as a go-to provider in this space, offering affordable ...

That came in response to a February lawsuit from a compounding trade group against the Food and Drug Administration's determination that the active ingredient in those drugs, semaglutide ...

inauthentic semaglutide drugs." Two weeks ago, Lilly sued an Indianapolis spa, Premier Weight Loss, claiming that it buys autoinjector pens filled with tirzepatide, cracks them open, breaking a ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide ... loss and diabetes medication tirzepatide, sold under the brand ...

The net annual cost of semaglutide (Wegovy, Novo Nordisk) was estimated at $8,412 and the net annual cost of tirzepatide (Zepbound, Eli Lilly) was estimated to be $6,236. The model assumed the ...

Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

That means it has more in common with Lilly's tirzepatide, which targets the same two receptors - semaglutide targets GLP-1 only. Viking is developing both a subcutaneous injectable and an oral ...